Responses of Patients with T3-4N0- 2 M0 Rectal Cancer to Preoperative Chemoradiotherapy: Review of Current Literature

M. Keita, M. Bah, SY Kondano, A. Camara, I. Cisse, M. Barry, W. Shen
{"title":"Responses of Patients with T3-4N0- 2 M0 Rectal Cancer to Preoperative Chemoradiotherapy: Review of Current Literature","authors":"M. Keita, M. Bah, SY Kondano, A. Camara, I. Cisse, M. Barry, W. Shen","doi":"10.15342/ijms.2022.617","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the efficacy and safety of chemoradiotherapy and radiotherapy followed by surgery in patients with locally advanced unresectable rectal cancer.Material and method: We reviewed records for 65 patients with locally advanced unresectable rectal cancer treated by preoperative chemoradiotherapy or radiotherapy followed by surgery between 2013 and 2016. Of these, 23 patients were treated with preoperative chemoradiotherapy (40 - 45 Gy) plus concomitant chemotherapy (5Fluorouracil + Calcium Folinate). For comparison, 42 similar patients, treated by preoperative radiotherapy (45 - 50Gy) plus surgery served as control. The primary end-point of the study was overall survival and local control rate.Results: No treatment plan was delayed because of toxicities in both groups. The radical resectability rate was 69.9 % in the chemoradiotherapy group and 33.3 % in the radiotherapy plus surgery group (P = 0. 024). The anal sphincter preservation rates were 26. 6 % and 3. 7 %, respectively (P= 0. 028). The anal sphincter preservation rates of the lower rectal cancer were 27. 3 % and 0. 0 %, respectively (P = 0. 014). Response rates of chemoradiotherapy and radiotherapy plus surgery groups were 82.6 % and 61.9 % (P = 0. 053). The tumor downstage rates were 16 (69.6%) and 24 (57.1%) in these groups (P = 0. 206). The 3-years overall survival rates were 66. 7 % and 55. 6 % (P = 0. 485), and the tumor-free survival rates were 40. 3 % and 33. 1 % (P = 0. 663) . The 3-years local recurrent rates were 26. 9 % and 48. 1 % (P = 0. 174) . No obvious late effects were found in either group. Conclusion: The results of this study suggested at least that acute side effects of preoperative chemoradiotherapy can be tolerated and a higher surgical resection rate can be achieved. However, the chemoradiotherapy did not improve the survival rate while it increased local recurrence due to the high rate of anal sphincter preservation. It is safe and effective to use 5-Fluorouracil + Calcium Folinate and 5 – DFUR as a radiosensitizer during the whole course of radiotherapy.","PeriodicalId":143308,"journal":{"name":"Integrative Journal of Medical Sciences","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15342/ijms.2022.617","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To investigate the efficacy and safety of chemoradiotherapy and radiotherapy followed by surgery in patients with locally advanced unresectable rectal cancer.Material and method: We reviewed records for 65 patients with locally advanced unresectable rectal cancer treated by preoperative chemoradiotherapy or radiotherapy followed by surgery between 2013 and 2016. Of these, 23 patients were treated with preoperative chemoradiotherapy (40 - 45 Gy) plus concomitant chemotherapy (5Fluorouracil + Calcium Folinate). For comparison, 42 similar patients, treated by preoperative radiotherapy (45 - 50Gy) plus surgery served as control. The primary end-point of the study was overall survival and local control rate.Results: No treatment plan was delayed because of toxicities in both groups. The radical resectability rate was 69.9 % in the chemoradiotherapy group and 33.3 % in the radiotherapy plus surgery group (P = 0. 024). The anal sphincter preservation rates were 26. 6 % and 3. 7 %, respectively (P= 0. 028). The anal sphincter preservation rates of the lower rectal cancer were 27. 3 % and 0. 0 %, respectively (P = 0. 014). Response rates of chemoradiotherapy and radiotherapy plus surgery groups were 82.6 % and 61.9 % (P = 0. 053). The tumor downstage rates were 16 (69.6%) and 24 (57.1%) in these groups (P = 0. 206). The 3-years overall survival rates were 66. 7 % and 55. 6 % (P = 0. 485), and the tumor-free survival rates were 40. 3 % and 33. 1 % (P = 0. 663) . The 3-years local recurrent rates were 26. 9 % and 48. 1 % (P = 0. 174) . No obvious late effects were found in either group. Conclusion: The results of this study suggested at least that acute side effects of preoperative chemoradiotherapy can be tolerated and a higher surgical resection rate can be achieved. However, the chemoradiotherapy did not improve the survival rate while it increased local recurrence due to the high rate of anal sphincter preservation. It is safe and effective to use 5-Fluorouracil + Calcium Folinate and 5 – DFUR as a radiosensitizer during the whole course of radiotherapy.
T3-4N0- 2m0直肠癌患者对术前放化疗的反应:文献综述
目的:探讨局部晚期不可切除直肠癌放化疗后手术治疗的疗效和安全性。材料和方法:我们回顾了2013 - 2016年65例局部晚期不可切除直肠癌术前放化疗或放疗后手术治疗的记录。其中,23例患者接受术前放化疗(40 - 45 Gy)加伴随化疗(5氟尿嘧啶+亚叶酸钙)。对照组42例,均行术前放疗(45 ~ 50Gy)加手术治疗。研究的主要终点是总生存率和局部控制率。结果:两组患者均未因毒副反应而延误治疗计划。放化疗组根治性切除率为69.9%,放化疗加手术组根治性切除率为33.3% (P = 0.05)。024)。肛门括约肌保存率为26%。6%和3。分别为7% (P= 0。028)。下段直肠癌肛门括约肌保留率为27。3%和0。分别为0% (P = 0。014)。放化疗组和放疗加手术组有效率分别为82.6%和61.9% (P = 0.05)。053)。两组肿瘤降期率分别为16例(69.6%)和24例(57.1%)(P = 0.05)。206)。3年总生存率为66。7%和55%。6% (p = 0。485例),无瘤生存率为40%。3%和33%。1% (p = 0。663)。3年局部复发率为26。9%和48%。1% (p = 0。174)。两组均未见明显的晚期效应。结论:本研究结果至少表明术前放化疗的急性副作用是可以耐受的,并且可以实现较高的手术切除率。然而,放化疗并没有提高生存率,反而由于肛门括约肌保留率高,增加了局部复发率。5-氟尿嘧啶+亚叶酸钙+ 5- DFUR作为放疗全程放射增敏剂是安全有效的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信